|Click on "►" to expand:|
 BRAND NAMES
 MECHANISM OF ACTION
Trimebutine maleate is an antispasmodic agent, its action on the gastrointestinal tract are mediated via:
- an agonist effect on peripheral mu, kappa and delta opiate receptors
- release of gastrointestinal peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin and glucagon.
Trimebutine does not alter normal motility, but regulates abnormal intestinal activity.
- Treatment of both acute and chronic abdominal pain in patients with functional bowel disorders, especially irritable bowel syndrome
- Postoperative paralytic ileus in order to accelerate the resumption of the intestinal transit following abdominal surgery.
- Adults: the recommended dose is 300-450 mg daily, before meals. Maximum: 600 mg daily
- Children >5 years: 50 mg 3 times a day.
Known hypersensitivity to Trimebutine
 PREGNANCY AND LACTATION
Trimebutine should not be used during the first trimester and may be used during the second and third trimester only if the potential benefit justifies the potential risk to the fetus .
It is not known if trimebutine maleate passes into breast milk. This medication should be used while breastfeeding only if the potential benefits outweigh risks to the nursing infants.
 SIDE EFFECTS
The commonly reported adverse effects are as follows:
- Gastrointestinal: Dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea and constipation were reported in total of 3.1% of the patient population.
- CNS: Drowsiness, fatigue, dizziness, hot/cold sensations and headaches were reported in 3.3%.
- Allergic reactions: Rash in 0.4% of the patients
- Miscellaneous effects: Menstrual problems, painful enlargement of breast, anxiety, urine retention and slight deafness were also infrequently reported.